In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 10, 1996, Pages 2237-2242

  Hata, Katsura ^a   Kimura, Junko ^a   Miki, Hikari ^a   Toyosawa, Toshio ^a   Nakamura, Toshihiro ^a   Katsu, Kanemasa ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDIASIS; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRICHOSPORON BEIGELII;

EID: 0029846116     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.10.2237     Document Type: Article

References (23)

1. Allendoerfer, R., D. Loebenberg, M. G. Rinaldi, and J. R. Graybill. 1995. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis. Antimicrob. Agents Chemother. 39:1345-1348.
2. Bossche, H. V., P. Marichal, F. C. Odds, L. Le Jeune, and M.-C. Coene. 1992. Characterization of azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 36:2602-2610.
3. DeGregorio, M. W., W. M. F. Lee, C. A. Linker, R. A. Jacobs, and C. A. Ries. 1982. Fungal infections in patients with acute leukemia. Am. J. Med. 73: 543-548.
4. Elewski, B. E. 1995. Trends in the management of cutaneous fungal infections. Jpn. J. Med. Mycol. 36:7-12.
5. Espinel-Ingroff, A., S. Shadomy, and R. J. Gebhart. 1984. In vitro studies with R51,211 (itraconazole). Antimicrob. Agents Chemother. 26:5-9.
6. George, D., P. Miniter, and V. T. Andriole. 1996. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 40:86-91.
7. Georgopapadakou, N. H., and T. J. Walsh. 1996. Antifungal agents: chemotherapeutic targets and immunologie strategics. Antimicrob. Agents Chemother. 40:279-291.
8. Graybill, J. R. 1989. New antifungal agents. Eur. J. Clin. Microbiol. Infect. Dis. 5:402-412.
9. Hay, R. J. 1991. Antifungal therapy and new azole compound. J. Antimicrob. Chemother. 28(Suppl. A):35-46.
10. Hector, R. F., and E. Yee. 1990. Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. Antimicrob. Agents Chemother. 34:448-454.
11. Hitchcock, C. A., G. W. Pye, P. F. Troke, E. M. Johnson, and D. W. Warnock. 1993. Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37:1962-1965.
12. Humphrey, M. J., S. Jevons, and M. H. Tarbit. 1985. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents Chemother. 28:648-653.
13. Kawasaki, K., Y. Matsumura, M. Ogawa, A. Tsuji, T. Matsunaga, and S. Goto. 1991. In vivo and in vitro antifungal activity of fluconazole. Jpn. J. Antibiot. 44:552-561.
14. Larsen, R. A. 1990. AIDS commentary: azoles and AIDS. J. Infect. Dis. 162:727-730.
15. Meyer, R. D., L. S. Young, D. Armstrong, and B. Yu. 1973. Aspergillosis complicating neoplastic disease. Am. J. Med. 54:6-15.
16. Naito, T., Y. Kaku, A. Tsuruoka, H. Kakinuma, I. Tsukada, M. Yanagisawa, and K. Nara. 1995. ER-30346, a novel antifungal agent: 1. Synthesis and structure-activity relationships of new thiazole-containing triazole antifungals, abstr. F91, p. 128. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
18. Pietroski, N. A., D. Pharm, and J. Stern. 1990. Cryptococcal meningitis and other fungal infections of the central nervous system. Curr. Opin. Infect. Dis. 3:608-613.
19. Richardson, K., K. W. Brammer, M. S. Marriott, and P. F. Troke. 1985. Activity of UK-49,858, a bistriazole derivative, against experimental infection with Candida albicans and Trichophyton mentagrophytes. Antimicrob. Agents Chemother. 27:832-835.
20. Tanino, T., K. Ichise, T. Nakajima, and T. Okuda. 1990. In vivo efficacy of SM-8668 (Sch 39304), a new triazole antifungal agent. Antimicrob. Agents Chemother. 34:980-984.
21. Troke, P. F., M. S. Marriott, K. Richardson, and M. H. Tarbit. 1988. In vitro potency and in vivo activity of azoles. Ann. N. Y. Acad. Sci. 544:284-293.
22. Yamada, H., T. Tsuda, T. Watanabe, M. Ohhashi, K. Murakami, and H. Mochizuki. 1993. In vitro and in vivo antifungal activities of D0870, a new triazole agent. Antimicrob. Agents Chemother. 37:2412-2417.
23. Yamaguchi, H., K. Makimura, H. Kume, and M. Okudaira. 1993. Recent trend of deep-seated mycoses in Japan and related medical problems. Prog. Med. 13:2675-2681.